Acrux Limited has released a press release.
Update - Licensing Lenzetto for Australia for AUD5.4m
Earlier from Acrux
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement
- Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido